Kallenbach K, Schwill S, Karck M
Klinik für Herzchirurgie, Universitätsklinikum Heidelberg, Interdisziplinäres Marfan-Zentrum Heidelberg, INF 110, 69120, Heidelberg, Deutschland.
Herz. 2011 Sep;36(6):505-12. doi: 10.1007/s00059-011-3502-z.
Marfan syndrome is a hereditary disease with a prevalence of 2-3 in 10,000 births, leading to a fibrillin connective tissue disorder with manifestations in the skeleton, eye, skin, dura mater and in particular the cardiovascular system. Since other syndromes demonstrate similar vascular manifestations, but therapy may differ significantly, diagnosis should be established using the revised Ghent nosology in combination with genotypic analysis in specialized Marfan centres. The formation of aortic root aneurysms with the subsequent risk of acute aortic dissection type A (AADA) or aortic rupture limits life expectancy in patients with Marfan syndrome. Therefore, prophylactic replacement of the aortic root needs to be performed before the catastrophic event of AADA can occur. The goal of surgery is the complete resection of pathological aortic tissue. This can be achieved with excellent results by using a (mechanically) valved conduit that replaces both the aortic valve and the aortic root (Bentall operation). However, the need for lifelong anticoagulation with Coumadin can be avoided using the aortic valve sparing reimplantation technique according to David. The long-term durability of the reconstructed valve is favourable, and further technical improvements may improve longevity. Although results of prospective randomised long-term studies comparing surgical techniques are lacking, the David operation has become the surgical method of choice for aortic root aneurysms, not only at the Heidelberg Marfan Centre. Replacement of the aneurysmal dilated aortic arch is performed under moderate hypothermic circulatory arrest combined with antegrade cerebral perfusion using a heart-lung machine, which we also use in thoracic or thoracoabdominal aneurysms. Close post-operative follow-up in a Marfan centre is pivotal for the early detection of pathological changes on the diseased aorta.
马凡综合征是一种遗传性疾病,在每10000例出生中患病率为2 - 3例,会导致一种原纤维蛋白结缔组织紊乱,在骨骼、眼睛、皮肤、硬脑膜尤其是心血管系统出现症状。由于其他综合征也表现出类似的血管症状,但治疗方法可能有显著差异,因此应在专门的马凡综合征中心使用修订的根特分类法结合基因分型分析来进行诊断。主动脉根部动脉瘤的形成以及随后发生A型急性主动脉夹层(AADA)或主动脉破裂的风险限制了马凡综合征患者的预期寿命。因此,需要在AADA灾难性事件发生之前进行主动脉根部的预防性置换。手术的目标是完全切除病理性主动脉组织。使用一种(机械)带瓣管道同时替换主动脉瓣和主动脉根部(Bentall手术)可以出色地实现这一目标。然而,根据大卫的方法,使用保留主动脉瓣再植入技术可以避免终身使用香豆素进行抗凝。重建瓣膜的长期耐久性良好,进一步的技术改进可能会提高其使用寿命。尽管缺乏比较手术技术的前瞻性随机长期研究结果,但大卫手术不仅在海德堡马凡综合征中心,已成为主动脉根部动脉瘤的首选手术方法。使用心肺机在中度低温循环骤停并结合顺行性脑灌注的情况下进行动脉瘤性扩张主动脉弓的置换,我们在胸主动脉或胸腹主动脉瘤手术中也采用这种方法。在马凡综合征中心进行密切的术后随访对于早期发现病变主动脉的病理变化至关重要。